Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

about

The Potential for Circulating Tumor Cells in Pancreatic Cancer Management.

P2860

Q33753267-C86DC190-96C6-445E-AA02-C96F1AE9CCE0

P2860

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

Item

http://www.wikidata.org/entity/Q45992759

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

@en

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

@nl

type

Item

label

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

@en

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

@nl

prefLabel

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

@en

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

@nl

P1476

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

@en

P2093

Martin E Fernandez-Zapico

http://www.w3.org/2001/XMLSchema#string

P2860

Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells

Genetics and biology of pancreatic ductal adenocarcinoma.

Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

What we have learned about pancreatic cancer from mouse models.

Therapeutic advances in pancreatic cancer.

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

P304

234-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1053/J.GASTRO.2016.06.032

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

151

http://www.w3.org/2001/XMLSchema#string

P50

Wayne K Dawson

P577

2016-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27374366

http://www.w3.org/2001/XMLSchema#string

P932

6042851

http://www.w3.org/2001/XMLSchema#string

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

about

P2860

P2860

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932